Physiologically based pharmacokinetic prediction of telmisartan in human

Drug Metabolism and Disposition

Volumn 42, Issue 10, 2014, Pages 1646-1655

  Li, Rui ^a   Ghosh, Avijit ^a   Maurer, Tristan S ^a   Kimoto, Emi ^a   Barton, Hugh A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONIDE; ORGANIC ANION TRANSPORTER; TELMISARTAN; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ARTICLE; CALIBRATION; CELL CULTURE; COMPUTER MODEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER CLEARANCE; LIVER MICROSOME; PARTITION COEFFICIENT; PHARMACOKINETICS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; BIOLOGICAL MODEL; COMPUTER SIMULATION; METABOLISM;

BENZIMIDAZOLES; BENZOATES; COMPUTER SIMULATION; HEPATOCYTES; HUMANS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS;

EID: 84907588697     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058461     Document Type: Article

References (43)

1. Bi YA, Kazolias D, and Duignan DB (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 34:1658-1665.
2. Casali AM, Siringo S, Sofia S, Bolondi L, Di Febo G, and Cavalli G (1994) Quantitative analysis of intrahepatic bile duct component in normal adult human liver and in primary biliary cirrhosis. Pathol Res Pract 190:201-206.
3. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
4. Ebner T, Heinzel G, Prox A, Beschke K, and Wachsmuth H (1999) Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos 27:1143-1149.
5. Furukawa T, Nakamori F, Tetsuka K, Naritomi Y, Moriguchi H, Yamano K, Terashita S, and Teramura T (2012) Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. Drug Metab Pharmacokinet 27:171-180.
6. Gallo JM, Lam FC, and Perrier DG (1987) Area method for the estimation of partition coefficients for physiological pharmacokinetic models. J Pharmacokinet Biopharm 15:271-280.
7. Gan J, Chen W, Shen H, Gao L, Hong Y, Tian Y, Li W, Zhang Y, Tang Y, and Zhang H, et al. (2010) Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol 70:870-880.
8. Gill KL, Houston JB, and Galetin A (2012) Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos 40:825-835.
9. Graham H, Walker M, Jones O, Yates J, Galetin A, and Aarons L (2012) Comparison of in-vivo and in-silico methods used for prediction of tissue: plasma partition coefficients in rat. J Pharm Pharmacol 64:383-396.
10. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
11. Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, Hirota T, Irie S, Shimizu H, and Noguchi T, et al. (2011) Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics 21:495-505.
12. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, and Sugiyama Y (2006) Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34: 1109-1115.
13. Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, and Rowland-Yeo K (2014) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet 53:73-87.
14. Jones HM, Parrott N, Jorga K, and Lavé T (2006) A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511-542.
15. Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, and Dickins M, et al. (2011) Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet 50:331-347.
16. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, and Galetin A, et al. (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-1017.
17. Kuhn JG (1998) Pharmacology of irinotecan. Oncology (Williston Park) 12(8, Suppl 6)39-42.
18. Li R, Barton HA, Yates PD, Ghosh A, Wolford AC, Riccardi KA, and Maurer TS (2014) A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling. J Pharmacokinet Pharmacodyn 41: 197-209.
19. Lindahl A, Sandström R, Ungell AL, Abrahamsson B, Knutson TW, Knutson L, and Lennernäs H (1996) Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin Pharmacol Ther 60:493-503.
20. Ménochet K, Kenworthy KE, Houston JB, and Galetin A (2012) Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos 40:1744-1756.
21. Miura M, Satoh S, Kagaya H, Saito M, Inoue T, Ohkubo T, Habuchi T, and Suzuki T (2009) Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. J Clin Pharm Ther 34:683-692.
22. Mück W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, and Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 35:255-260.
23. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, and Neuvonen PJ (2005) Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468-478.
24. Obach RS, Lombardo F, and Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385-1405.
25. Poirier A, Cascais AC, Funk C, and Lavé T (2009) Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn 36:585-611.
26. Poulin P and Theil FP (2000) A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16-35.
27. Roberts MS, Magnusson BM, Burczynski FJ, and Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790.
28. Rodgers T and Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
29. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
30. Schlyer DJ (2004) PET tracers and radiochemistry. Ann Acad Med Singapore 33:146-154.
31. Shah DK and Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39:67-86.
32. Shimizu K, Takashima T, Yamane T, Sasaki M, Kageyama H, Hashizume Y, Maeda K, Sugiyama Y, Watanabe Y, and Senda M (2012) Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. Nucl Med Biol 39:847-853.
33. Stangier J, Schmid J, Türck D, Switek H, Verhagen A, Peeters PA, van Marle SP, Tamminga WJ, Sollie FA, and Jonkman JH (2000a) Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 40:1312-1322.
34. Stangier J, Su CA, and Roth W (2000b) Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 28:149-167.
35. U.S. Food and Drug Administration (1998) Micardis (Telmisartan) NDA 20850 Pharmacology Reviews, Center for Drug Evaluation and Research, pp 27-28, available at: http://www.accessdatafdagov/drugsatfda-docs/nda/98/20850-MICARDIS-pharmr-P1.pdf.
36. Wallenstein GC, Stangier J, and Ludden TM (1999) Analyzing rich data using different methods provided by NONMEM: pharmacokinetics of telmisartan following intravenous infusion to healthy volunteers. Pharm Res 16:772-776.
37. Wang M, Shan B, Li W, Wang M, and Su X (2009) Influence of indapamide on pharmacokinetics of telmisartan in male and female rats. Chi J Pharmacol Toxicol 23:1-5.
38. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
39. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, Jonkman JH, and Jones CR (1996) Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124-137.
40. Wienen W and Entzeroth M, Jacobus Cvan Meel A, Stangier J, Busch U, Ebner T, Schmid J, Lehmann H, Matzek K, and Kempthorne-Rawson J, et al. (2000) A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 18:127-154.
41. Yamada A, Maeda K, Ishiguro N, Tsuda Y, Igarashi T, Ebner T, Roth W, Ikushiro S, and Sugiyama Y (2011) The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics 21:523-530.
42. Yun YE and Edginton AN (2013) Correlation-based prediction of tissue-to-plasma partition coefficients using readily available input parameters. Xenobiotica 43:839-852.
43. Zhang R, Liu T, Soong SJ, and Diasio RB (1993) A mathematical model of the kinetics and tissue distribution of 2-fluoro-beta-alanine, the major catabolite of 5-fluorouracil. Biochem Pharmacol 45:2063-2069.